OPA1 and breast cancer: In addition, due to OPA1’s anti-apoptotic function, its targeting using MYLS22 or Opitor-0 synergizes with the BCL-2 inhibitor ABT-737 in paclitaxel-resistant breast cancer cell lines [155].